

Evaluation of the extended regimen versus standard regimen of oral contraceptive in premenstrual and/or menstrual symptoms

Submission date 26/08/2010	Recruitment status No longer recruiting	☒ Prospectively registered
Registration date 05/10/2010	Overall study status Completed	☐ Protocol
Last Edited 15/04/2020	Condition category Urological and Genital Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Achilles Cruz

Contact details
250 Josef Kryss
São Paulo
Brazil
01140-050

Additional identifiers

Protocol serial number
LB0901

Study information

Scientific Title

A randomised multicentre parallel-group, comparative, prospective, open label study to assess the effect of extended regimen versus standard regimen of the oral contraceptive 3 mg drospirenone/20 µg ethinyl estradiol in premenstrual and/or menstrual symptoms

Study objectives

This study aims to show the non-inferiority of the extended regimen compared to standard regimen of the oral contraceptive drospirenone/ethinyl estradiol in the treatment of premenstrual and/or menstrual symptoms.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the Faculty of Medicine Jundiai approved on the 5th August 2010 (ref: 176 /10)

Study design

Randomised double-arm multicentre comparative prospective parallel groups open label trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Premenstrual symptoms

Interventions

Subjects will be randomised to receive either 3 mg drospirenone/20 µg ethinyl estradiol in extended regimen (168 days of uninterrupted treatment) or drospirenone 3 mg/ethinyl estradiol 20 µg in standard regimen (6 cycles of 24 days of treatment followed by 4-day tablet free interval).

Subjects will record the scores of symptoms and patterns of bleeding in a daily diary. Questionnaire for Quality of Life (Short WHOQOL) will be applied in visits C1 (after 1 month of treatment), C2 (after 3 months of treatment) and C4 (after 6 months of treatment).

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Drospirenone, ethinyl estradiol

Primary outcome(s)

Percentage of reduction in the total score of symptoms as recorded in the Daily Symptom Report (DSR-17) after treatment with 3 mg drospirenone/20 µg ethinyl estradiol in extended regime compared to standard regime.

Key secondary outcome(s))

1. Bleeding pattern
2. Questionnaire for Quality of Life (Short WHOQOL) - Portuguese version, applied in visits C1,

C3 and C4

3. Significant change in laboratory tests and clinical parameters

Completion date

28/02/2012

Eligibility

Key inclusion criteria

1. Females of child bearing age (18 - 39 years)
2. At least three regular menstrual cycles lasting between 25 and 35 days, with 3 - 7 days of bleeding, without occurrence of intermenstrual bleeding and without amenorrhoea
3. Willingness to contraception and to meet the requirements of the study
4. Available to receive telephone calls
5. Competence to consent to participate in the study and sign the ICF
6. Education of at least four years or good ability to understand spoken and written information as testified by investigator
7. Complaint of at least one physical symptom and one emotional symptom in the premenstrual and/or menstrual period with intensity greater than or equal to two points according to scores of "Daily Symptom Report (DSR-17)" recorded by patient in the screening phase

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Total final enrolment

348

Key exclusion criteria

1. Users of hormonal contraceptives less than three months before the study. Exception will be considered to users of combined oral contraceptives without drospirenone in formulation, used in conventional 21/7 regimen.
2. Use of depot medroxyprogesterone acetate less than six months before the study
3. History of severe depression, bipolar disorder, psychosis, history of drug or alcohol abuse in the past two years
4. Treatment with antidepressants or anxiolytics
5. Any condition in category 2, 3 or 4 of the Medical Eligibility Criteria of the World Health Organization for contraceptive use, except for smoking**
6. Women smoking more than 15 cigarettes/day or smokers aged over 35 years

7. Use of drugs that interfere with the effectiveness of combined oral contraceptives
8. Suspected or confirmed pregnancy
9. Clinically significant changes in laboratory parameters requested in the screening visit
10. Participation in another trial less than three months before the study
11. Relationship to staff members of the study

Date of first enrolment

10/01/2011

Date of final enrolment

28/02/2012

Locations

Countries of recruitment

Brazil

Study participating centre

250 Josef Kryss

São Paulo

Brazil

01140-050

Sponsor information

Organisation

LIBBS Farmaceutica Ltd (Brazil)

ROR

<https://ror.org/055kp8612>

Funder(s)

Funder type

Industry

Funder Name

LIBBS Farmaceutica Ltd (Brazil)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	30/03/2020	15/04/2020	Yes	No